Physician profile
Shanan B Munoz
NPI 1528075132
$74,877.31
in general payments reported to CMS, 2019-2025
14 companies · $9,073 in 2025
The $9,073 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $17K · 2021: $6,115 · 2022: $14K · 2023: $5,367 · 2024: $1,974 · 2025: $9,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $2,486 · Travel and Lodging: $240 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Education: $57.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,430.00 |
| Food and Beverage | $2,485.95 |
| Travel and Lodging | $240.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Education | $57.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $18,269.13 | 2019-2025 | Tysabri |
| Emd Serono, INC. | $14,243.78 | 2019-2025 | Mavenclad |
| Genentech USA, INC. | $12,857.91 | 2019-2025 | Ocrevus |
| Genzyme Corporation | $12,047.17 | 2019-2025 | |
| Horizon Therapeutics Plc | $6,278.52 | 2021-2022 | |
| Tg Therapeutics, INC. | $4,533.07 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $4,283.50 | 2019-2025 | Kesimpta |
| Celgene Corporation | $1,564.23 | 2019-2022 | |
| Banner Life Sciences, LLC | $800.00 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanan Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.